These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 3546358)
21. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Rains CP; Bryson HM; Fitton A Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332 [TBL] [Abstract][Full Text] [Related]
22. Discordant responses of prolactinoma to two different dopamine agonists. Ahmed SR; Shalet SM Clin Endocrinol (Oxf); 1986 Apr; 24(4):421-6. PubMed ID: 3742834 [TBL] [Abstract][Full Text] [Related]
23. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Webster J Drug Saf; 1996 Apr; 14(4):228-38. PubMed ID: 8713691 [TBL] [Abstract][Full Text] [Related]
24. Pregnancy and Tumor Outcomes in Women with Prolactinoma. Araujo B; Belo S; Carvalho D Exp Clin Endocrinol Diabetes; 2017 Nov; 125(10):642-648. PubMed ID: 28704852 [No Abstract] [Full Text] [Related]
25. Hyperprolactinemia and prolactinoma. Romijn JA Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588 [TBL] [Abstract][Full Text] [Related]
26. [Medical treatment of prolactin and growth hormone-secreting pituitary tumors]. Jadresic A Rev Med Chil; 1997 Nov; 125(11):1383-8. PubMed ID: 9609063 [TBL] [Abstract][Full Text] [Related]
27. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. Liuzzi A; Dallabonzana D; Oppizzi G; Verde GG; Cozzi R; Chiodini P; Luccarelli G N Engl J Med; 1985 Sep; 313(11):656-9. PubMed ID: 4022058 [TBL] [Abstract][Full Text] [Related]
28. Prolactin and reproductive medicine. Davis JR Curr Opin Obstet Gynecol; 2004 Aug; 16(4):331-7. PubMed ID: 15232488 [TBL] [Abstract][Full Text] [Related]
29. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when? Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552 [TBL] [Abstract][Full Text] [Related]
30. Bromocriptine therapy: Review of mechanism of action, safety and tolerability. Naz F; Malik A; Riaz M; Mahmood Q; Mehmood MH; Rasool G; Mahmood Z; Abbas M Clin Exp Pharmacol Physiol; 2022 Aug; 49(8):903-922. PubMed ID: 35635035 [TBL] [Abstract][Full Text] [Related]
35. [Drug therapy of hyperprolactinemia, acromegaly and Cushing syndrome]. Marek J; Rezábek K; Srámková J Z Gesamte Inn Med; 1983 Nov; 38(22):246-8. PubMed ID: 6666180 [TBL] [Abstract][Full Text] [Related]
36. The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review. Weil C Curr Med Res Opin; 1986; 10(3):172-95. PubMed ID: 3525009 [TBL] [Abstract][Full Text] [Related]
38. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas. Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009 [TBL] [Abstract][Full Text] [Related]
39. [Current diagnosis and treatment of hyperprolactinemia]. Melgar V; Espinosa E; Sosa E; Rangel MJ; Cuenca D; Ramírez C; Mercado M Rev Med Inst Mex Seguro Soc; 2016; 54(1):111-21. PubMed ID: 26820213 [TBL] [Abstract][Full Text] [Related]
40. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography. Johnston DG; Hall K; Kendall-Taylor P; Patrick D; Watson M; Cook DB Lancet; 1984 Jul; 2(8396):187-92. PubMed ID: 6146751 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]